An interventional study of Green coffee extract and Beta glucan in Overweight/Obesity and Insulin Resistance, sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición. Completed at 1 site in Spain. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-08-17.
Sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 390 studies in Obesity with a site in Spain — 95 open to participants now, 134 under way, 45 of them phase 3. Obesity · Spain.
Among the 390 studies in Obesity with a site in Spain, this one is the 305th largest by enrollment of the 332 interventional ones that give a count, is one of 26 that started in 2018, is one of 220 with no phase, and was the 177th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →95 of the 390 studies in Obesity with a site in Spain are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Spain, United States, Germany and 1 more country
Ages 45–65 · Women only
Boehringer Ingelheim · Sites in Spain, United States, Germany and 1 more country
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Argentina and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Belgium and 7 more countries
Ages 6–11
AstraZeneca · Sites in Spain, United States, Argentina and 13 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
390 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 24 · Phase 3 81 · Phase 4 7
First in 2001; this study’s year is marked. 26 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 124 across the 332 interventional studies, 128 across the 57 observational. Of the 208 that completed or were terminated, 26 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
121 of 390 have an industry lead sponsor. The 10 most frequent:
Instituto de Ciencia y Tecnología de Alimentos y Nutrición is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Instituto de Ciencia y Tecnología de Alimentos y Nutrición has 3 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
33 of the studies in Obesity with a site in Spain that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07332273Phase 3Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludLevothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity. | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
Add all 33 to your calendar (.ics) → With an account.
Among the 390 studies in Obesity with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aimed at assessing the effect of a decaffeinated green coffee extract, rich in hydroxycinnamates, oat beta-glucans or the combination of both bioactive compounds on overweight/obese subjects with hyperglycemia.
In a randomized, crossover, blind, three-arm study, volunteers consumed twice a day a nutraceutical providing 5 g/d beta-glucan (BG), 600 mg/d green coffee polyphenols (GC) or a combination of both (5 g/d BG + 600 mg/d GC). Each intervention stage lasted 8 weeks and was followed by a 4-week wash-out.
Blood, urine and fecal samples were obtained at the beginning and end of each intervention stage. Blood pressure, oral glucose tolerance test (OGTT) and body composition (body weight, anthropometry, bioimpedance) were measured at each control visit. Physical activity was controlled by accelerometry (1 week during each intervention stage). Energy expenditure was measured by calorimetry. Food intake was monitored by 3-d food records. Satiety was determined by subjective (VAS) and objective (weighting consumed food) records after consuming the nutraceutical during each intervention stage.
In a subset of volunteers (9), a pharmacokinetic study was performed to assess bioavailability and metabolism of polyphenols at the beginning and end of each intervention (GC and GC+BG only). In these volunteers, blood was taken at different times during 24 h; urine samples were also collected at different intervals during 24 h, and feces were obtained at 0 and 24 h approximately after consuming the nutraceuticals containing GC. A targeted metabolomic analysis was carried out in these samples. In these volunteers, incretins and hormones were also determined in blood samples.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's enrollment of 30 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Browse Obesity studies →Instituto de Ciencia y Tecnología de Alimentos y Nutrición is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nutraceutical containing a decaffeinated green coffee extract rich in phenolic compounds (hydroxycinnamates). Participants received powdered sachets containing 300 mg of GC extract twice daily for 8 weeks
Dietary Supplement: Green coffee extract
Nutraceutical containing a oat beta-glucan. Participants received powdered sachets containing 2.5 g of BG twice daily for 8 weeks
Dietary Supplement: Beta glucan
Nutraceutical containing both green coffee extract and beta-glucan. Participants received powdered sachets containing 2.5 g of BG plus 300 mg of GC extract twice daily for 8 weeks
Dietary Supplement: Green coffee + beta-glucan
150 mg polyphenols from green coffee, twice daily
2.5 g BG twice daily
150 mg polyphenols from green coffee + 2.5 g BG, twice daily
Body weight
Change of body weight (estimated 2.5 kg) at the end of the intervention
Time frame: 8 weeks
Body fat percentage
Change of body fat percentage (total and visceral)
Time frame: 8 weeks
Anthropometry
Change of body circumferences (waist, hip, thigh) or skin folds at the end of the intervention
Time frame: 8 weeks
Insulin resistance
Change in fasting blood glucose and/or insulin levels, use to calculate homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR), beta-cell function (HOMA-beta) or quantitative insulin sensitivity check index (QUICKI) indexes. Outcome would be a modification of at least one of these indexes at the end of the intervention
Time frame: 8 weeks
Blood lipids
Modification of serum levels of total cholesterol, LDL-cholesterol, HDL-cholesterol blood, triglycerides at the end of the intervention
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2018 to primary completion in Dec 2019, 12 months.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 12 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beta-Glucans
Instituto de Ciencia y Tecnología de Alimentos y Nutrición